Effectiveness of calcipotriol/betamethasone dipropionate aerosol foam in patients with small versus large plaque psoriasis in routine practice in South Korea

• Published in: Journal of dermatology Vol. 51; no. 7; pp. 1010 - 1016
• Main Authors: Jo, Seong Jin, Park, Chul‐Jong, Bang, Chul Hwan, Jeong, Ki‐Heon, Shin, Bong Seok, Kim, Dong Hyun, Song, Hae Jun, Lee, Ju‐Hee, Kim, YoungEun, Choi, Sun, Youn, Sang Woong
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.07.2024; John Wiley and Sons Inc
• Subjects: Adult; Aerosols; Aged; Betamethasone - administration & dosage; Betamethasone - analogs & derivatives; betamethasone dipropionate; calcipotriol; Calcitriol - administration & dosage; Calcitriol - analogs & derivatives; Concise Communication; Dermatologic Agents - administration & dosage; Drug Combinations; Female; fixed dose combination; Humans; Immunoglobulin A; Korean psoriasis; Male; Middle Aged; Patients; plaque size; Plaques; Pruritus; Psoriasis; Psoriasis - diagnosis; Psoriasis - drug therapy; Psoriasis - pathology; Quality of Life; Republic of Korea; Severity of Illness Index; Statistical analysis; Treatment Outcome; Republic of Korea; South Korea; calcipotriol; Korean psoriasis; betamethasone dipropionate; plaque size; fixed dose combination
• ISSN: 0385-2407; 1346-8138; 1346-8138
• DOI: 10.1111/1346-8138.17253

Small plaque psoriasis is the typical form of chronic plaque psoriasis affecting adults in South Korea. The effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) aerosol foam for large and small psoriasis plaques has not previously been examined. We performed a post hoc analysis of a recent, 4‐week observational study of Cal/BD aerosol foam use in routine clinical practice in South Korea. Investigator Global Assessment response ([IGA] 0/1 at week 4), Patient Global Assessment response ([PaGA] 0/1 at week 4), change in Psoriasis Area and Severity Index (PASI), changes in psoriasis symptom scores, change in the Dermatology Life Quality Index (DLQI), and the proportion of patients achieving DLQI ≤5 were analyzed for patients with small (≤5 cm; n = 131) or large (>5 cm; n = 35) baseline plaque size. IGA response rates were similar for patients with small and large plaques (59.5% and 51.4% respectively). Similarly, there was no significant difference between the small and large groups in mean change in PASI (−2.20 vs −3.34), the proportions of patients with DLQI ≤5 (62.3% vs 54.3%) or PaGA 0/1 (29.2% vs 40.0%). Mean improvements in DLQI (−4.04 vs −6.20) and in psoriasis symptoms including itching (−1.50 vs −2.83), sleep loss (−0.67 vs −1.89), dryness (−1.57 vs −2.97), scaling (−1.21 vs −3.57), and redness (−1.17 vs −3.11) were greater in patients with large plaques than those with small plaques. Itching and DLQI differences were not statistically significant after adjustment for baseline characteristics. Stratification by body surface area affected eliminated statistically significant differences between the groups for most outcomes. In conclusion, this analysis suggests that Cal/BD aerosol foam is an effective, well‐accepted treatment for adult patients with the small plaques typical of chronic plaque psoriasis in South Korea, as well as for those with large plaques.